Ver­tex Phar­ma­ceu­ti­cals an­nounced Fri­day af­ter­noon that it won’t move for­ward with its type 1 di­a­betes cell ther­a­py that’s de­liv­ered in a … ...

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of thePhase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55, marking a +0.45% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.33%.

Google’s Gemini 2.5 Pro is available now in Google AI Studio and in the Gemini app for Gemini Advanced users, and will be coming to Vertex AI soon. But let’s be real—AI models are often ...

Testing across these three characteristics has demonstrated promising results, including >98% concentricity and a twofold improvement in fatigue durability through microstructural refinement. The ...

Gemini 2.5 Pro (experimental) is rolling out first to Gemini Advanced and Google AI Studio, with Vertex AI following in the coming weeks. We’ll also introduce pricing in the coming weeks ...

Vertex Trading Down 1.2 % NASDAQ VERX opened at $35.71 on Monday. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.04 and a current ratio of 1.04. Vertex, Inc. has a one year low ...

Venture capital investor Vertex Ventures Japan (VVJ) announced the first close of its inaugural fund, Vertex Ventures Japan Fund I (VVJFI), which targets 10 billion yen (about $67 million) in total ...